Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 15/20 | 0.43 |
| ▸ | NMBR | P28336 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3976810 | 0.93 | SIRT2 (0.45) | SIRT2NMBRCYP11B1CYP11B2ENPP2 | |
| SCHEMBL24329386 | 0.89 | SIRT2 (0.36) | SIRT2KDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL5439663 | 0.85 | SIRT2 (0.42) | SIRT2NMBRCYP11B1CYP11B2ENPP2 | |
| SCHEMBL3821641 | 0.81 | SIRT2 (0.46) | SIRT2NMBRCYP11B1CYP11B2ENPP2 | |
| SCHEMBL2796109 | 0.79 | SIRT2 (0.52) | SIRT2CYP11B1CYP11B2 | |
| SCHEMBL1039638 | 0.78 | SIRT2 (0.43) | SIRT2NMBRCYP11B1CYP11B2 | |
| SCHEMBL2490264 | 0.77 | SIRT2 (0.48) | SIRT2NMBRUSP2LMNAALOX15 | |
| SCHEMBL10914340 | 0.77 | KDM4E (0.33) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL4379824 | 0.77 | SIRT2 (0.43) | SIRT2KDM4EALDH1A1LMNA | |
| SCHEMBL25309477 | 0.77 | SIRT2 (0.41) | SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382949-A1 | LINEAR APELIN RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-11-30 | — | — | US | disclosed |
| US-20230382949-A1 | LINEAR APELIN RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-11-30 | — | — | US | disclosed |
| EP-1200430-A4 | THIOUREA AND ISOTHIOUREA DERIVATIVES FOR INHIBITING RAS-TRANSFORMED CELL GROWTH | YUHAN CORP LTD (KR) | 2003-01-22 | — | — | EP | disclosed |
| EP-1200430-A1 | THIOUREA AND ISOTHIOUREA DERIVATIVES FOR INHIBITING RAS-TRANSFORMED CELL GROWTH | YUHAN CORPORATION, LTD. (KR) | 2002-05-02 | — | — | EP | disclosed |
| WO-2001009128-A1 | THIOUREA AND ISOTHIOUREA DERIVATIVES FOR INHIBITING RAS-TRANSFORMED CELL GROWTH | YUHAN CORPORATION (KR) | 2001-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382949-A1 | LINEAR APELIN RECEPTOR AGONISTS | APLNR, MTNR1A, EDNRA | SIRT2 4152/4885NMBR 387/4885KDM4E 3435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.